Last reviewed · How we verify
VEN combined with azacitidine
VEN combined with azacitidine works by inhibiting DNA methyltransferase and histone deacetylase, leading to epigenetic modifications that promote cell differentiation and apoptosis in cancer cells.
VEN combined with azacitidine works by inhibiting DNA methyltransferase and histone deacetylase, leading to epigenetic modifications that promote cell differentiation and apoptosis in cancer cells. Used for Acute myeloid leukemia.
At a glance
| Generic name | VEN combined with azacitidine |
|---|---|
| Sponsor | Nanfang Hospital, Southern Medical University |
| Drug class | Hypomethylating agent and histone deacetylase inhibitor |
| Target | DNA methyltransferase and histone deacetylase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Azacitidine is a hypomethylating agent that inhibits DNA methyltransferase, leading to increased expression of tumor suppressor genes. VEN, a histone deacetylase inhibitor, further promotes cell differentiation and apoptosis by modifying chromatin structure.
Approved indications
- Acute myeloid leukemia
Common side effects
- Myelosuppression
- Fatigue
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia (PHASE2)
- A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients (PHASE2)
- A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) (PHASE3)
- Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML (PHASE3)
- A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies (PHASE1)
- A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy (PHASE2)
- Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR) (PHASE2)
- Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: